The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM

NCT03174522 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

49

Enrollment

INDUSTRY

Sponsor class

Stopped Independent Data Monitoring Committee recommendation to stop due to futility

Conditions

Peripheral Arterial Disease (PAD)
Diabetes Mellitus (DM)
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Cardiovascular Disease
Critical Limb Ischemia (CLI)

Interventions

DRUG: REX-001
DRUG: Placebo

Sponsor

Ixaka Ltd

Collaborators

[object Object]